Danish drugmaker Novo Nordisk has raised its full-year guidance, citing stronger-than-expected demand for its obesity and diabetes treatments, especially outside the United States. The company's flagship weight-loss drug, Wegovy, continues to expand its market presence as the rollout of its oral pill version gains momentum. Executives noted that international markets are now contributing significantly to revenue growth, offsetting softer U.S. performance in recent quarters. The improved outlook reflects both increased prescription volumes and favorable pricing dynamics in key regions. Novo Nordisk remains a dominant player in the rapidly growing GLP-1 agonist space, with competitors racing to catch up. The update signals confidence in the long-term trajectory of its metabolic disease portfolio.
Investors responded positively, sending shares higher in early trading. Analysts suggest the revised forecast underscores the company’s manufacturing scalability and distribution reach. While the U.S. remains the largest market, the diversification into Europe, Asia, and Latin America is proving vital. The oral Wegovy pill is expected to broaden access for patients who prefer non-injectable options. Novo Nordisk plans to continue investing in R&D to expand indications and formulations.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing